Read by QxMD icon Read

Journal of Clinical Psychiatry

Norma Verdolini, Giulia Menculini, Giulio Perugi, Andrea Murru, Ludovic Samalin, Jules Angst, Jean-Michel Azorin, Charles L Bowden, Sergey Mosolov, Allan H Young, Margherita Barbuti, Dina Popovic, Eduard Vieta, Isabella Pacchiarotti
OBJECTIVE: This post hoc analysis of the BRIDGE-II-MIX study is aimed at evaluating affective lability (AL) as a possible clinical feature of mixed depression and assessing the relationship with atypical depressive features, particularly mood reactivity (MR). METHODS: In the BRIDGE-II-MIX multicenter, cross-sectional study, 2,811 individuals suffering from a major depressive episode (MDE; DSM-IV-TR criteria), in the context of bipolar I or II disorder (BD-I, BD-II, respectively) or major depressive disorder, were enrolled between June 2009 and July 2010...
February 19, 2019: Journal of Clinical Psychiatry
John Lauriello, Diana O Perkins
Schizophrenia is a chronic disorder that can be effectively controlled but will likely require lifelong treatment. Unfortunately, most patients experience numerous relapses, ongoing symptoms, and impairment, often because of treatment interruptions. Continuous treatment is imperative to prevent relapse and the potentially devastating consequences that can follow a return of psychotic symptoms. Clinicians must better monitor a common cause of relapse, nonadherence, and offer strategies to improve adherence. Strategies can target the patient, the environment, or treatment...
February 19, 2019: Journal of Clinical Psychiatry
Axel Haglund, Henrik Lysell, Henrik Larsson, Paul Lichtenstein, Bo Runeson
OBJECTIVE: The risk of suicide is elevated after discharge from a psychiatric hospital. This study aimed to investigate how recent suicidal behavior affects the risk of suicide in patients with different psychiatric diagnoses immediately after discharge. METHODS: Registers with national coverage were linked to create a study cohort including all individuals discharged from psychiatric hospitals in Sweden from 1973 through 2009. Hazard ratios for discharge diagnoses were calculated...
February 12, 2019: Journal of Clinical Psychiatry
Kelly E Moore, Lindsay M S Oberleitner, Howard V Zonana, Alec W Buchanan, Brian P Pittman, Terril L Verplaetse, Gustavo A Angarita, Walter Roberts, Sherry A McKee
OBJECTIVE: Current knowledge regarding the intersection of psychiatric disorders and crime in the United States is limited to psychiatric, forensic, and youth samples. This study presents nationally representative data on the relationship of DSM-5 psychiatric disorders, comorbid substance and mental health disorders, and multimorbidity (number of disorders) with criminal behavior and justice involvement among non-institutionalized US adults. METHODS: Data were drawn from the National Epidemiologic Survey on Alcohol and Related Conditions Wave III (NESARC-III; 2012-2013; N = 36,309)...
February 12, 2019: Journal of Clinical Psychiatry
Chittaranjan Andrade
Cataract is a common disease of the eye, and depression is common in patients with cataract. This raises the possibility that depression and the drugs used to treat depression may be risk factors for cataract. In a recent systematic review and meta-analysis of 7 case-control studies with a pooled sample of 447,672 cases and 1,510,391 controls, antidepressant drugs were associated with a very small but statistically significant increase in the risk of cataract; the odds ratios for different classes of antidepressants were in the 1...
January 29, 2019: Journal of Clinical Psychiatry
Myuri Ruthirakuhan, Krista L Lanctôt, Danielle Vieira, Nathan Herrmann
OBJECTIVE: This meta-analysis investigated the efficacy of cannabinoids on agitation and aggression in patients with Alzheimer's disease (AD). DATA SOURCES: Electronic records up to August 2018 were searched from MEDLINE, EMBASE, and PsycINFO. Search terms included Alzheimer's disease, agitation, aggression, and cannabinoids. STUDY SELECTION: Double-blind, placebo-controlled studies investigating the effect of cannabinoids on agitation in patients with AD were included...
January 29, 2019: Journal of Clinical Psychiatry
Eric T Dobson, Michael H Bloch, Jeffrey R Strawn
OBJECTIVE: To evaluate the efficacy and tolerability of pharmacotherapy in pediatric anxiety disorders using network meta-analysis. DATA SOURCES: PubMed, Cochrane Database, Web of Science, PsycNET, and were searched for double-blind, controlled pharmacotherapy trials in youth with anxiety disorders from 1966 to September 2017. DATA SELECTION: All double-blind, placebo-controlled trials of pharmacotherapy in the treatment of pediatric patients with generalized, social, and/or separation anxiety disorders were included...
January 29, 2019: Journal of Clinical Psychiatry
Chittaranjan Andrade
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Antidepressant drugs are known to influence cardiac conduction, and there are theoretical grounds to suggest that serotonin reuptake inhibition by antidepressants may predispose to AF. A large register-based cohort study found that antidepressant use was associated with an increased risk of AF during the first month following antidepressant initiation. Whereas this may seem alarming, additional analyses found that the risk progressively diminished in succeeding months...
January 22, 2019: Journal of Clinical Psychiatry
Hamideh Bayrampour, Jeffrey Trieu, Thayanthini Tharmaratnam
Objective: eHealth interventions have been shown to be effective in improving anxiety among the general population. Despite the effectiveness of eHealth interventions for perinatal depression, a recent review reported mixed results for perinatal anxiety. The review, however, was not focused on anxiety, and studies with various designs were included. The aim of this systematic review is to summarize the evidence specific to anxiety and to conduct a meta-analysis to examine the effectiveness of eHealth interventions in reducing perinatal anxiety...
January 22, 2019: Journal of Clinical Psychiatry
Christina M Temes, Frances R Frankenburg, Garrett M Fitzmaurice, Mary C Zanarini
OBJECTIVE: This study has 4 aims. The first is to determine rates of mortality due to suicide and other causes for patients with borderline personality disorder (BPD) and personality-disordered comparison subjects over 24 years of prospective follow-up. The second and third aims are to determine the best predictors of time-to-suicide and time-to-premature death (not due to suicide) in patients with BPD. A final aim is to determine whether mortality rates are impacted by recovery status...
January 22, 2019: Journal of Clinical Psychiatry
Joshua A Gordon
No abstract text is available yet for this article.
January 15, 2019: Journal of Clinical Psychiatry
Mark Zimmerman, Caroline Balling, Kristy Dalrymple, Iwona Chelminski
OBJECTIVE: Borderline personality disorder (BPD) is a serious illness that is frequently underdiagnosed. A previous psychometric analysis of the 9 BPD criteria in DSM-IV/DSM-5 found that the affective instability criterion functioned well as a screen for the disorder. A limitation of that initial study was that the performance of the BPD criteria was examined in a diagnostically heterogeneous sample, including those with a low likelihood of having BPD. The present study from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project examined the operating characteristics of the BPD criteria in patients with major depressive disorder (MDD) and bipolar disorder...
January 15, 2019: Journal of Clinical Psychiatry
E Fuller Torrey, Robert H Yolken, H Richard Lamb
No abstract text is available yet for this article.
January 15, 2019: Journal of Clinical Psychiatry
Markus Dold, Lucie Bartova, Alexander Kautzky, Stefano Porcelli, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz, Daniel Souery, Alessandro Serretti, Siegfried Kasper
OBJECTIVE: To elucidate the impact of the presence of psychotic features in patients diagnosed with major depressive disorder (MDD) on sociodemographic, psychosocial, clinical, and response characteristics. METHODS: A total of 1,410 DSM-IV-TR MDD patients were included in the present European multicenter study, which was conducted between 2011 and 2016. Analyses of covariance, χ² tests, and binary logistic regression analyses were performed to explore differences in sociodemographic and clinical variables between MDD patients with and without psychotic symptoms...
January 15, 2019: Journal of Clinical Psychiatry
Christoph U Correll, Steven G Potkin, Yan Zhong, Judit Harsányi, Balázs Szatmári, Willie Earley
BACKGROUND: Long-term remission is an important treatment goal in schizophrenia. Cariprazine, a dopamine D₃/D₂ receptor and serotonin 5-HT1A receptor partial agonist, is approved in the United States and Europe to treat adults with schizophrenia. METHODS: Post hoc analyses of data from a long-term cariprazine relapse prevention study (NCT01412060; September 27, 2011-September 3, 2014) investigated the efficacy of cariprazine for maintaining remission in clinically stable patients with DSM-IV-TR-defined schizophrenia...
January 8, 2019: Journal of Clinical Psychiatry
Marlene P Freeman
No abstract text is available yet for this article.
January 8, 2019: Journal of Clinical Psychiatry
David Misdrahi, Arnaud Tessier, Antoine Daubigney, Wassilios G Meissner, Franck Schurhoff, Laurent Boyer, Ophélia Godin, Ewa Bulzacka, Bruno Aouizerate, Meja Andrianarisoa, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau-Boudet, Thierry D'Amato, Caroline Dubertret, Julien Dubreucq, Catherine Faget-Agius, Christophe Lançon, Jasmina Mallet, Christine Passerieux, Romain Rey, Aurélie Schandrin, Mathieu Urbach, Pierre Vidailhet, Pierre-Michel Llorca, Guillaume Fond
BACKGROUND: Extrapyramidal side effects (EPS) have been identified as a complication of antipsychotic treatment. Previous meta-analyses have investigated EPS prevalence and risk factors in randomized clinical trials with highly selected patients, but studies in real-world schizophrenia are missing. OBJECTIVE: To examine the prevalence and clinical correlates associated with EPS in a nonselected national multicenter sample of stabilized patients with schizophrenia...
January 8, 2019: Journal of Clinical Psychiatry
John S Shelton
No abstract text is available yet for this article.
January 8, 2019: Journal of Clinical Psychiatry
Christoph U Correll, Andrew J Cutler, John M Kane, Joseph P McEvoy, Grace S Liang, Christopher F O'Brien
BACKGROUND: In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1-7). Data from this study were analyzed further to provide a more clinically meaningful interpretation of the primary AIMS results. METHODS: The study included adults who had a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or any mood disorder and also met DSM-IV criteria for neuroleptic-induced TD...
December 18, 2018: Journal of Clinical Psychiatry
Teddy J Akiki, Chadi G Abdallah
No abstract text is available yet for this article.
December 18, 2018: Journal of Clinical Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"